file image. , Photo Credit: Reuters
Pharma giant Abbott India Pvt Ltd has issued a public notice on April 25 asking it to voluntarily recall a batch of Thyronorm tablets due to a labeling error. The company said that this particular batch has been invoiced only in Telangana and Madhya Pradesh.
Due to error, a small percentage of bottles in a batch have been incorrectly labeled with a dosage strength of 25 mcg whereas the bottles contained 88 mcg tablets. Thyronorm is a drug used in the treatment of hypothyroidism.
Meanwhile, the Drug Control Administration of the Telangana government issued a circular on Tuesday directing all the drug inspectors of the state to keep a close watch on the movement of the concerned drug batch. The inspectors have been asked to submit compliance reports to the Joint Director.
People who have recently purchased Thyronorm with batch number AEJ0713, manufacturing date of March 2023 and expiry date of February 2025, are requested to return the bottle to the chemist from whom they purchased it, in notice Having said.
in a statement issued on Hindu It was stated by a spokesperson for Abbott that “there are no quality issues with the product and we have not received any reports of patient impact. It is important that people take the correct dose, so we have voluntarily recalled the mislabelled batch”. We are working with our distributors and other partners to facilitate this recall.